Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Average Recommendation of “Buy” from Analysts

Jasper Therapeutics, Inc. (NASDAQ:JSPR) has been given an average recommendation of “Buy” by the nine analysts that are currently covering the firm, Marketbeat Ratings reports. Nine investment analysts have rated the stock with a buy rating. The average 1 year target price among analysts that have covered the stock in the last year is $74.86.

Several brokerages have weighed in on JSPR. Evercore ISI reissued an “outperform” rating and set a $65.00 price target on shares of Jasper Therapeutics in a research report on Monday, August 26th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Jasper Therapeutics in a research note on Monday, September 9th. HC Wainwright restated a “buy” rating and set a $65.00 target price on shares of Jasper Therapeutics in a research report on Thursday, October 24th. Royal Bank of Canada lowered their price target on shares of Jasper Therapeutics from $70.00 to $68.00 and set an “outperform” rating on the stock in a report on Wednesday, August 14th. Finally, JMP Securities reissued a “market outperform” rating and issued a $70.00 target price on shares of Jasper Therapeutics in a report on Tuesday, October 15th.

Jasper Therapeutics Stock Performance

JSPR stock opened at $20.02 on Tuesday. The firm has a market cap of $302.30 million, a P/E ratio of -4.22 and a beta of 2.19. The firm’s fifty day moving average is $20.26 and its 200 day moving average is $20.89. Jasper Therapeutics has a 52 week low of $4.00 and a 52 week high of $31.01.

Hedge Funds Weigh In On Jasper Therapeutics

Institutional investors have recently made changes to their positions in the company. Russell Investments Group Ltd. acquired a new stake in Jasper Therapeutics during the 1st quarter worth $2,343,000. Bank of New York Mellon Corp purchased a new stake in Jasper Therapeutics during the second quarter worth about $740,000. American Century Companies Inc. increased its stake in Jasper Therapeutics by 27.1% during the second quarter. American Century Companies Inc. now owns 14,204 shares of the company’s stock worth $322,000 after purchasing an additional 3,032 shares during the period. Ikarian Capital LLC purchased a new stake in shares of Jasper Therapeutics during the first quarter worth approximately $3,088,000. Finally, Wolff Wiese Magana LLC acquired a new position in Jasper Therapeutics in the third quarter valued at approximately $59,000. 79.85% of the stock is owned by hedge funds and other institutional investors.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.